Scroll to top
Prion Protein Mutation Database

Architecture of PrP

In humans, a single exon encodes the 253 amino acid (aa) prepro-PrPC 1 (see PrP Gene Structure) of 32-35 kDa mass; differential splicing does not occur. A 22 aa signal peptide is cleaved from the N-terminus during synthesis in the endoplasmic reticulum and the 23 residue attachment signal sequence on the C-terminus is cleaved upon addition of a glycosyl phosphoinositol (GPI) anchor at serine 2302, through which PrPC tethers to the extracellular leaflet of the plasma membrane. Mature PrPC (residues 23-230) is composed of an independent and flexible, random coil N-terminal region (residues 23-124) and a rigid globular C-terminal domain (residues 125-230) – Figure 1. PrPC is correctly folded before being transported to the Golgi complex, where is it differentially glycosylated to either un-, mono- or di-glycosylated species of PrPC 3-4. The sequence and structure of PrPC is highly conserved across mammalian species. Insertions and deletions are the most common pathogenic mutations leading to prion disease in the N-terminal coil, whereas, in the globular domain, missense mutations predominate5 (see Schematic of Pathogenecity).

Figure 1: Architecture of PrP. Upper panel: the PRNP primary translation product, preproPrPC, formed of 253 amino acids (aa) with cleavable N- and C-termini signal peptide (22 aa) and GPI anchor (23 aa) sequences, respectively. This yields a 208 aa mature protein. Middle panel: mature PrPC domain annotation is shown. The charged clusters, CC1 and CC2, are shown in grey. The octapeptide repeat region, where binding of Cu2+ or Zn2+ occurs is shown in royal blue. The hydrophobic region is in powder blue, and the palindrome and conserved glycines are highlighted. Secondary structural elements are shown in light blue for b-sheets and purple for the a-helices. The single disulphide bond in PrPC, between Cys179 and Cys214 is shown, as are the two variably occupied asparagine glycosylation sites at N181 and N179. Lower panel: the gross arrangement of PrPC is shown, with the N-terminal flexible coil and the globular C-terminal domain.


The unstructured N-terminal region of PrPC contains several important functional elements (Figure 1). The first region of importance spans residues 51-91; it contains a nonapeptide, PQGGGGWGQ, followed by an octapeptide repeat region [PHGGGWGQ](aa 60-91)6 that coordinates copper and zinc with high affinity7-12. There are also two polybasic charged clusters, CC1 (KKRPK at residues 23-27) and CC2 (KPSKPKTNMK at residues 101-110), as well as an hydrophobic region (residues 112-134) containing an alanine-rich palindrome of residues AGAAAAGA (residues 113-120). It is of note that the octapeptide repeat domain is among the most highly conserved regions of the prion protein13. In contrast, the globular domain contains all the acidic residues of the chain14. The complementary polybasic stretches (CC1 and CC2) in the N-terminus and electronegative surfaces from the globular C-terminus provide the mechanism for molecular compaction that is stabilised by Cu2+ and Zn2+ binding14.

The PrPC N-terminus binds both copper and zinc in vivo and participates in metal ion homeostasis (see PrP Function). Cu2+ and Zn2+ ions coordinate to the N-terminal differently – Cu2+ interacts with the octapeptide repeat domain11-12, and also with residues His96 and His1119-10, whereas, all four histidine residues in the octapeptide repeat domain coordinate a single Zn2+ ion with a dissociation constant of approximately 200 mM9,15-16. Residues HGGGW in each octapeptide repeat constitutes the fundamental Cu2+-binding unit10. Most of the copper ions bind in a domain composed of tandem PHGGGWGQ repeats. At low Cu2+ occupancy, coordination is provided by three or four His imidazoles; at high occupancy, coordination is from the His imidazole and deprotonated amide-nitrogen atoms of the two Gly residues that immediately follow His. The high occupancy coordination mode stabilises Cu2+ over Cu+ and thus suppresses copper-redox activity. The affinity for Cu2+ varies significantly, with Kd values of 0.12 nM at low occupancy and Kd 7-12 mM, at high occupancy. Such affinities are well matched to the known Cu2+ concentrations in the synapse where PrP is localised and is highly suggestive of a role in neuronal metal ion homeostasis10,15.


Figure 2: Chemistry of the Cu2+-octapeptide repeat interaction. Panel A shows the Cu2+-HGGGW complex at high occupancy, involving coordination through deprotonated amide nitrogens and exhibits weaker affinity characterised by a Kd in the range of 7.0 – 12.0 mM. Panel B shows binding at low occupancy, which favours multiple His coordination and binds the octapeptide repeat domain with a lower dissociation constant (Kd 0.12 nM), and thus, higher affinity10.

Beyond localised coordination, both Cu2+ and Zn2+, promote long-range quaternary structure interactions in PrPC 17-18; octapeptide repeat metal binding results in a cis interaction between the flexible N-terminal domain and the globular C-terminus, an association that is stabilised by electrostatic charge complementarity between the polybasic N-terminus clusters, CC1 and CC2, and a negatively charged patch on the C-terminal globular domain14,19. There is emerging evidence to suggest that this interaction serves as a critical regulatory element in PrP physiology and in suppression of neurotoxicity15-16,19. Evans et al19 have shown that Cu2+-bound octapeptide repeat region interacts with a specific region of the globular C-terminal domain defined by the exposed surface of a-helices 2 and 3, as well as the N-terminal portion of a-helix 1 (mouse PrP numbering: α-helix 1, I138, F140-W144, Y149-R150; α-helix 2, N172, V175-H176, V179-N180, T187; α-helix 3, E199, E206-R207, E210-Q211). The N-terminus interacts with the same globular domain surface (mouse PrP numbering: α-helix 1, M137, I138, F140-D143, D146, Y149-R150, N152-M153; α-helix 2, Q171, N172-N173, H176-D177, V179, I181, T187-V188, T190, G194, α-helix 3, D201, E206, V209, Q211) when studied using Cd2+ as a proxy for Zn2+ 16. Notably, the globular domain docking surface is formed of a highly conserved, electronegative pocket15,19 and these residues overlap with the epitopes of PrP antibodies known to cause severe acute neurotoxicity15,20-21.

The majority of PRNP gene mutations that give rise to human prion disease result in point mutations on helices a2 and a3, and often involve amino acid substitutions that attenuate the overall negative charge of this domain5,22-23. Furthermore, with Zn2+ coordinated, several point mutations corresponding to human PrPCmutations E200K and D178N, were shown to decrease the apparent strength of this cis interaction17. Patients with octapeptide repeat insertion mutations, have an earlier onset of prion disease5,22, and this may, in part, be due to alteration of the cis interaction with the globular C-terminal domain. Deletion of one octapeptide repeat occurs as an uncommon polymorphism in the European population22, however, deletion of two repeats is pathogenic5,24. This again may relate to disruption of the N-terminus-C-terminus structural dynamics, as at least three octapeptide segments are required to bind Cu2+ and mediate the interaction9,19. It is therefore, plausible that a disruption of metal-mediated cis interaction, and hence of the quaternary PrP fold, may be a causative factor in prion-mediated toxicity and certain inherited prion diseases. In support of this notion, is the finding that both Cu2+ and Zn2+ arrest in vitro PrPSc amplification17,25. It is then interesting to note that deletion of the entire N-terminal domain is found to be benign in transgenic mice26 and this protein retains its conversion potential to PrPSc 27. However, internal N-terminal deletions that retain the CC1 cluster are neurotoxic26 and deletions that leave greater portions of the N-terminus intact are progressively more neurologically damaging15,28.

The N-terminal hydrophobic region (residues 112-134, Figure 1) has a predicted high propensity for b-sheet secondary structure, thought to undergo significant structural transition following prion infection – as antibodies directed toward mouse PrP residues 90-120 detect PrPC but not PrPSc 29 – and is proposed to be involved in PrPc-PrPSc interaction, as a misfolding initiation site that effects prion propagation30-32. Indeed, cells transfected with a PrP transgene that expresses mutant PrP with a deletion of the AGAAAAGA palindrome (residues 113-120) cannot be infected with PrPSc 33, indicating the necessity of the palindrome for PrPC to PrPSc conversion. Furthermore, peptides that include the AGAAAAGA region inhibit in vitro conversion of PrPCto PrPSc in a cell-free conversion model, again underlining the importance of these amino acids in the PrPC-PrPSc interaction and subsequent prion propagation34-35.

In addition to the palindrome, the hydrophobic core is glycine rich, and arranged in GXXXG motifs; a frequent motif in transmembrane a-helices that is reported to stabilise helix-helix associations and permit close packing of transmembrane domains36. The glycine residues in this region show perfect conservation across all mammalian species identified to date13,37-38 . Relatively conservative amino acid substitutions of the glycine residues in this region, as well as mouse homologues of the pathogenic G114V and A117V mutations, have been shown to diminish prion propagation and infectivity – reinforcing the importance of the hydrophobic region in conversion of PrPC to PrPSc 37-38. Furthermore, the most neurotoxic deletion mutant in mice, as determined by the relative amount of wild-type expression required to rescue the phenotype, involves deletion of the hydrophobic region, however, these PrPC mutants do not form PrPSc 15,28,39.

Conforming with the above findings, a Gly127Val polymorphism (in the hydrophobic domain) localised to the region in Papua New Guinea affected by the Kuru epidemic, was found to confer resistance to Kuru5,40.  The protection provided by this variant was replicated in transgenic mice expressing human PrP41, whereby, heterozygous Gly127Val mice exhibited profoundly reduced susceptibility to infection with kuru and classical CJD prions, and Val127 homozygosity conferred complete resistance to all inoculated prion strains41. The structural mechanism underlying this intrinsic resistance to prion propagation has recently been elucidated42. It has been shown that the Val127 polymorphism alters the regional backbone geometry, and consequently facilitates greater stability of dimeric Val127 PrPC assembly through increased inter-molecular hydrogen bonding and extension of the dimer interface. This in turn, is thought to affect the conversion potential of Gly127Val to PrPSc and account for the powerful effect of this polymorphism on prion disease42. This proposed mechanism is supported by two lines of evidence: first, the PrPC dimerisation surface has been mapped to the hydrophobic region43; and second, PrPC dimerisation inhibits PrPSc and prion replication44-45. These findings contrast with the influential PrPC codon 129 polymorphism that also modulates prion disease susceptibility. Methionine is the ancestral amino acid at position 129; 37% of the UK population are Met homozygotes, 12% are Val homozygotes, and 51% are Met/Val heterozygous at this site. At position 129, it is homozygosity for either methionine or valine that predisposes to iatrogenic and sporadic CJD, whereas the heterozygous state confers significant protection against these prion diseases. Unlike the mechanism revealed for the Gly127Val variant, this is thought to occur through inhibition of homotypic PrP interactions46-49. Of note, the Glu219Lys polymorphism, found in the Japanese population, is also associated with resistance to sporadic CJD50. It is similarly thought that variant Glu219Lys sequesters PrPC from PrPSc conversion by preventing homologous dimerisation, but this is suggested to occur through alteration of the surface charge distribution51..

The globular C terminus contains three a-helices (residues: α1, 144-154; α2, 173-194; and α3, 200-228) and a short anti-parallel b-sheet (residues: β1, 128-131 and β2, 161-164). These elements are assembled in two parts, β1-α1-α2 and α2-α3, in the hydrophobic core52-53. A single disulphide bond stabilises the globular domain and two variably occupied asparagine-linked glycosylation sites (N181 and N197) lie within a loop formed by the Cys179-Cys214 bridge53-56. It has been proposed that reduction of this disulphide bond, as could occur in intra-cellular compartments, may act as a structural trigger that initiates prion propagation57. The tertiary structure of mouse PrP globular domain was solved by NMR in 199658. Since that time, high resolution PrP structures have been determined for an array of mammalian species53,59-65; they have collectively revealed a highly conserved fold (Figure 3). Furthermore, comparison of PrPC purified from bovine brain, and recombinantly produced bovine PrP in Escherichia coli, displayed a similar structure, indicating that glycosylation and the GPI anchor do not affect the overall PrP fold66.

Figure 3: Sequence and structure conservation PrP across mammalian species. Panel A: Annotated alignment of selected mammalian species, for which a high-resolution structure has been determined. Panel B: Superposition of the globular C terminal domain of PrP in those selected species is shown.

Despite important scientific advances, the relationship between pathogenic PRNP mutations, PrP structure and prion disease phenotype remains incompletely understood. Mutations in the globular domain are predominantly concentrated in the region of the β2-α2 loop and in the α2-α3 inter-helical interface (Figure 4). See individual mutation pages for detailed discussion of each pathogenic missense variant (PrP Mutation Map).

Figure 4: Location of pathogenic mutations on PrPC. Shown is the NMR structure of human PrPC, onto which all pathogenic missense mutations are mapped. Mutant residues are shown as black Cα spheres. The structure on the right is rotated xx° about the y-axis, relative to the structure on the left.


  1. Puckett C, Concannon P, Casey C et al. Genomic Structure of the Human Prion Protein Gene. The American Journal of Human Genetics 1991; 49(2): 320-329. (PMID:1678248)
  2. Stahl N, Borchelt DR, Hsiao K and Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987; 51(2): 229-240.
  3. Meyer RK, McKinley MP, Bowman KA et al. Separation and properties of cellular and scrapie prion proteins. Proceedings of the National Academy of Sciences USA 1986; 83(8): 2310-2314.
  4. Yusa S-I, Oliveira-Martins JB, Sugita-Konishi Y, Kikuchi Y. Cellular Prion Protein: From Physiology to Pathology 2012; 4(11): 3109-3131.
  5. Mead S, Lloyd S, Collinge J. Genetic Factors in Mammalian Prion Diseases. Annual Review of Genetics 2019; 53: 117-147. (PMID: 31537104)
  6. Oesch B, Westaway D, Wälchli M et al. A Cellular Gene Encodes Scrapie PrP 27-30 Protein. Cell 1985; 40: 735-746.
  7. Stockel J, Safar J, Wallace AC et al. Prion protein selectively binds copper (II) IONS. Biochemistry 1998; 37(2): 185-193. (PMID: 9585530)
  8. Viles JH, Cohen FE, Prusiner SB et al. Copper binding to the prion protein: Structural implications of four identical cooperative binding sites. Proceedings of the National Academy of Sciences USA 1999; 96(5): 2042-2047. (PMID: 10051591)
  9. Walter ED, Stevens DJ, Visconte MP et al. The prion protein is a combined zinc and copper binding protein: Zn2+ alters the distribution of C2+ coordination modes. Journal of the American Chemical Society 2007; 129(50): 15440-15441.
  10. Millhauser GL. Copper and the Prion Protein: Methods, Structures, Function and Disease. Annual Review of Physical Chemistry 2007; 58: 299-320. (PMID: 17076634)
  11. Burns CS, Aronoff-Spencer E, Dunham CM et al. Molecular features of the copper binding sites in the octarpeat domain of the prion protein. Biochemistry 2002; 41(12): 3991-4001. (PMID: 11900542)
  12. Burns CS, Aronoff-Spencer E, Legname G et al. Copper coordination in the full-length, recombinant prion protein. Biochemistry 2003; 42(22): 6794-6803. (PMID: 12779334)
  13. Wopfner F, Weidenhöfer G, Schneider R et al. Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. Journal of Molecular Biology 1999; 289(5): 1163-1178. (PMID: 10373359)
  14. Martínez J, Sánchez R, Castellanos M et al. PrP charge structure encodes interdomain interactions. Scientific Reports 2015; 5: 13623. (PMID: 26323476)
  15. Evans EGB and Millhauser GL. Copper- and Zinc-Promoted Interdomain Structure in the Prion Protein: A mechanism for Autoinhibition of the Neurotoxic N-terminus. Progress in Molecular Biology and Translational Science 2017; 150: 35-56. (PMID: 28838668)
  16. Markham KA, Roseman GP, Linsley RB et al. Molecular Features of the Zn2+ Binding Site in the Prion Protein Probed by 113Cd NMR. Biophysical Journal 2019; 116(4): 610-620. (PMID: 30678993)
  17. Spevacek AR, Evans EGB, Miller JL et al. Zinc Drives a Tertiary Fold in the Prion Protein with Familial Disease mutation Sites at the Interface. Structure 2013; 21(2): 236-246. (PMID: 23290724)
  18. Thakur AK, Srivastava AK, Srinivas V et al. Copper alters aggregation behaviour of prion protein and indiced novel interactions between its N- and C-terminal regions. Journal of Biological Chemistry 2011; 286(44): 38533-38545. (PMID: 21900252)
  19. Evans EGB, Pushie MJ, Markham KA et al. Interaction between Prion Protein’s Copper-Bound Octarepeat Domain and a Charged C-Terminal Pocket Suggests a Mechanism for N-Terminal Regulation. Structure 2016; 24(7): 1057-1067. (PMID: 27265848)
  20. Reiman RR, Sonati T, Hornemann S et al. Differential Toxicity of Antibodies to the Prion Protein. PLOS Pathogens 2016; 12(1): e1005401. (PMID: 26821311)
  21. Sonati T, Reimann RR, Falsig J et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 2013; 501(7465): 102-106. (PMID: 23903654)
  22. Mead S. Prion disease genetics. European Journal of Human Genetics 2006; 14(3): 273-281. (PMID: 16391566)
  23. Shen L and Ji H-F. Mutation directional selection sheds light on prion pathogenesis. Biochemical and Biophysical Research Communications 2011; 410(2): 159-163. (PMID: 21679685)
  24. Beck JA, Poulter M, Campbell TA et al. PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit. Human Mutation 2010; 31(7): E1551-E1563. (PMID: 20583301)
  25. Orem NR, Geoghegan JC, Deleault NR et al. Copper (II) ions potentially inhibit purified PrPres amplification. Journal of Neurochemistry 2006; 96(5): 1409-1415. (PMID: 16417569)
  26. Westergard L, Turnbaugh JA, Harris DA. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. Journal of Biological Chemistry 2011; 286(51): 44234-44242. (PMID: 22025612)
  27. Fischer M, Rülicke T, Raeber A et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO Journal 1996; 15: 1255-1264.
  28. Baumann F, Tolnay M, Brabeck C et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. The EMBO Journal 2007; 26: 538-547.
  29. Peretz D, Williamson RA, Matsunaga Y et al. A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. Journal of Molecular Biology 1997; 273(3): 614-622. (PMID: 9356250)
  30. Norstrom EM and Mastrianno JA. The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation. Journal of Biological Chemistry 2005; 280(29): 27236-27243. (PMID: 15917252)
  31. Aguzzi A, Baumann F, Bremer J. The Prion’s Elusive Reason for Being. Annual Review of Neuroscience 2008; 31: 439-477.
  32. Abskharon R, Wang F, Wohlkonig A et al. Structural evidence for the critical role of the prion protein hydrophobic region in forming an infectious prion. PLOS Pathogens 2019; 15(12): e1008139. (PMID: 31815959)
  33. Hölscher C, Delius H, Bürke A. Overexpression of nonconvertible PrPc delta114-121 in scpraie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. Journal of Virology 1998; 72(2): 1153-1159. (PMID: 9445012)
  34. Brown DR. Prion Protein Peptides: Optimal Toxicity and Peptide Blockade of Toxicity. Molecular and Cellular Neuroscience 2000; 15(1): 66-78. (PMID: 10662506)
  35. Chabry J, Priola SA, Wehrly K et al. Species-independent Inhibition of Abnormal Prion Protein (PrP) Formation by a Peptide Containing a Conserved PrP Sequence. Journal of Virology 1999; 73(8): 6245-6250.
  36. Russ WP and Engelman DM. The GXXXG motif: a framework for transmembrane helix-helix association. Journal of Molecular Biology 2000; 296(3): 911-919. (PMID: 10677291)
  37. Harrison CF, Lawson VA, Coleman BM et al. Conservation of a Glycine-rich Region in the Prion Protein Is Required for Uptake of Prion Infectivity. Journal of Biological Chemistry 2010; 285(26): 20213-20223. (PMID: 20356832)
  38. Coleman BM, Harrison CF, Guo B et al. Pathogenic Mutations within the Hydrophobic Domain of the Prion Protein Lead to the Formation of protease-Sensitive Prion Species with Increased Lethality. Journal of Virology 2014; 88(5): 2690-2703.
  39. Li A, Christensen HM, Stewart LR et al. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. The EMBO Journal 2007; 26: 548-558.
  40. Mead S, Whitfield J, Poulter M et al. A novel protective prion protein variant that colocalises with kuru exposure. New England Journal of Medicine 2009; 361(21): 2056-2065. (PMID: 19923577)
  41. Asante EA, Smidak M, Grimshaw A et al. A naturally occurring variant of the human prion protein completely prevents prion disease. Nature 2015; 522(7557): 478-481. (PMID: 26061765)
  42. Hosszu LLP, Conners R, Sanger D et al. Structural effects of the highly protective V127 polymoprhism on human prion protein. Communications Biology 2020; 3(1): 402. (PMID: 327-28168)
  43. Rambold AS, Müller V, Ron U et al. Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO Journal 2008; 27(14): 1974-1984. (PMID: 18566584)
  44. Meier P, Genoud N, Prinz M et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonises prion disease. Cell 2003; 113(1): 49-60. (PMID: 12679034)
  45. Engelke AD, Gonsberg A, Thapa S et al. Dimerisation of the cellular prion protein inhibits propagation of scrapie prions. Journal of Biological Chemistry 2018; 293(21): 8020-8031. (PMID:29636413)
  46. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337: 1441
  47. Palmer MS, Dryden AJ, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991; 352(6333): 340-342. (PMID: 1677164)
  48. Wadsworth JDF and Collinge J. Molecular pathology of human prion diseases. Acta Neuropathologica 2011; 121(1): 69-77. (PMID: 20694796)
  49. Collinge J. Molecular neurology of prion disease. Journal of Neurology, Neurosurgery and Psychaitry 2005; 76(7): 906-919. (PMID: 15965195)
  50. Shibuya S, Higuchi J, Shin RW et al. Codon 219 Lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease. Annals of Neurology 1998; 43(6): 826-828. (PMID: 9629853)
  51. Biljan I, Giachin G, Ilc G et al. Structural basis for the protective effect of the human prion protein carrying the dominant-negative E219K polymorphism. Biochemical Journal 2012; 446(2): 243-251. (PMID: 22676969)
  52. Calzolai L and Zahn R. Influence of pH on NMR Structure and Stability of the Human Prion Protein Globular Domain. Journal of Biological Chemistry 2003; 278: 35592-35596.
  53. Zahn R, Liu A, Lührs T et al. NMR solution structure of the human prion protein. Proceedings of the National Academy of Sciences USA 2000; 97(1): 145-150. (PMID: 10618385)
  54. Brown K and Mastrianni JA. The Prion Diseases. Journal of Geriatric Psychiatry and Neurology 2010; 23(4): 277-298. (PMID: 20938044)
  55. Bernardi L and Bruni AC. Mutations in Prion Protein Gene: Pathogenic Mechanisms in C-Terminal vs. N-Terminal Domain, a Review. International Journal of Molecular Sciences 2019; 20(14): 3606. (PMID: 31340582)
  56. Atkinson CJ, Zhang K, Munn AL et al. Prion protein scrapie and the normal cellular prion protein. Prion 2016; 10(1): 63-82. (PMID: 26645475)
  57. Jackson GS, Hosszu LLP, Power A et al. Reversible Conversion of Monomeric Human Prion Protein Between Native and Fibrilogenic Conformations. Science 1999; 283(5409): 1935-1937. (PMID: 10082469)
  58. Riek R, Hornemann, Wider G et al. NMR structure of the mouse prion protein domain PrP (121-231). Nature 1996; 382(6587): 180-182. (PMID: 8700211)
  59. Lopez-Garcia F, Zahn R, Riek R, Wüthrich K. NMR structure of the bovine prion protein. Proceedings of the National Academy of Sciences USA 2000; 97(15): 8334-8339. (PMID: 10899999)
  60. Haire LF, Whyte SM, Vasisht N et al. The crystal structure of the globular domain of sheep prion protein. Journal of Molecular Biology 2004; 336(5): 1175-1183. (PMID: 15037077)
  61. Gossert AD, Bonjour S, Lysek DA et al. Prion protein NMR structures of elk and of mouse/elk hybrids. Proceedings of the National Academy of Sciences USA 2005; 102(3): 646-650. (PMID: 15647363)
  62. James TL, Liu H, Ulyanov NB et al. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proceedings of the National Academy of Sciences USA 1997; 94(19): 10086-10091. (PMID: 9294167)
  63. Lysek DA, Schorn C, Nivon LG et al. Prion protein NMR structures of cats, dogs, pigs and sheep. Proceedings of the National Academy of Sciences USA 2005; 102(3): 640-645. (PMID: 15647367)
  64. Christen B, Perez DR, Hornemann S, Wüthrich K. NMR structure of the bank vole prion protein at 20 degrees C contains a structured loop of residues 165-171. Journal of Molecular Biology 2008; 383(2): 306-312. (PMID: 18773909)
  65. Christen B, Hornemann S, Damberger FF, Wüthrich K. Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects. Journal of Molecular Biology 2009; 389(5): 833-845. (PMID: 19393664)
  66. Hornemann S, Schorn C, Wüthrich K. NMR structure of the bovine prion protein isolated from healthy calf brains. EMBO Reports 2004; 5(12): 1159-1164. (PMID: 15568016)